Taysha Gene Therapies, Inc.
TSHANASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $1.48B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $3.46$7.30
- Volume (live)
- -
- Avg. volume (3M)
- 4.72M
Taysha Gene Therapies (TSHA) Stock Price & Financial Analysis
Taysha Gene Therapies Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.94 - $4.18 |
|---|---|
| 52-Week High | $7.30 |
| 52-Week Low | $3.46 |
| Open | $4.07 |
| Volume (last close) | 3.11M |
| Average Volume (3M) | 4.72M |
| Revenue (TTM) | 5.49M |
|---|---|
| Net Income (TTM) | -149.63M |
| Free Cash Flow (TTM) | -135.57M |
| EPS (TTM) | −$0.42 |
| Profit Margin | -2728.04% |
| Operating Margin | -2854.91% |
| Return on Equity (ROE) | -38.64% |
| Debt to Equity | 0.13 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.48B |
|---|---|
| Shares Outstanding | 369.04M |
| Price to Sales (P/S) | 269.47 |
| Price to Book (P/B) | 3.82 |
| EV/EBITDA | -7.19 |
| 50-Day MA | $5.16 |
|---|---|
| 200-Day MA | $5.36 |
| 1-Year Change | −18.93% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Taysha Gene Therapies at a Glance
As of the Oct 22, 2026 close, Taysha Gene Therapies (TSHA) has a market capitalization of $1.48B. The stock trades at 269.5× sales. Over the trailing twelve months it lost $149.63M on revenue of $5.49M and burned $135.57M of free cash flow. Revenue fell 32.3% year over year.
As of its latest reported balance sheet, it holds $455.41M in cash and securities against $49.26M of debt, a net cash position of $406.15M.
Taysha Gene Therapies does not currently pay a dividend.
The share price is down 18.9% over the past year. At $4.00 (the Oct 22, 2026 close) it sits near the bottom of its 52-week range of $3.46 to $7.30, below its 200-day moving average of $5.36.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $14.00, 249.6% above the Oct 22, 2026 close.
Frequently Asked Questions About Taysha Gene Therapies
What is the current stock price for TSHA?
As of the Oct 22, 2026 close, TSHA stock trades at $4.00. The 52-week range is $3.46–$7.30, with a day range of $3.94–$4.17.
What is the P/E ratio for TSHA?
The P/E ratio (Price-to-Earnings) for TSHA is shown in the Key Statistics section. This valuation metric helps compare Taysha Gene Therapies, Inc. to industry peers.
Does TSHA pay dividends?
Taysha Gene Therapies does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for TSHA?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for TSHA is Buy. The average 12-month price target is $14.00, a 249.6% upside from the Oct 22, 2026 close of $4.00.
What is the market cap of TSHA?
As of the Oct 22, 2026 close, Taysha Gene Therapies's market capitalization is $1.48B, classifying it as a small-cap company. Taysha Gene Therapies operates in the Healthcare sector within the Biotechnology industry.